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TO THE EDITORvon Willebrand Disease
After TAVR
The Missing Link?By abolishing the obstruction created by a highly
stenotic aortic valve, transcatheter aortic valve
replacement (TAVR) is an effective treatment for
severe aortic stenosis, with a hemodynamic proﬁle
(mean gradient and aortic valve area) at least similar
or even superior to conventional surgical aortic valve
replacement (1). However, the presence of para-
valvular leak (PVL) after TAVR has been shown to be
associated with increased mortality (2). Although a
negative impact on left ventricular recovery and
remodeling has been proposed as the primary causal
mechanism (3), the exact pathophysiology of PVL and
its association with increased mortality remains to be
completely understood.
Spangenberg et al. (4) elegantly demonstrated that
although TAVR was successful in resolving the
detrimental hematologic impact of aortic stenosis in
most patients, PVL was associated with a persistent
breakdown of high molecular weight von Willebrand
factor (vWF), suggesting an increase in ﬂow turbu-
lence. Although this ﬁnding is extremely interesting,
the low number of patients (N ¼ 95) included in their
study precludes any deﬁnitive conclusion regarding
the clinical implication of acquired vWF disease after
TAVR, both from a bleeding and mortality point of
view.
From a large cohort of 2,401 patients in the
randomized PARTNER (Placement of AoRTic TraNs-
cathetER Valve Trial), we recently demonstrated
that the strongest predictor of bleeding events be-
tween 30 days and 1 year after successful TAVR was
the presence of moderate to severe PVL (5). Although
some may argue that PVL may represent a marker of
patients’ sickness rather than a causal factor leading
to mortality, we suggested that signiﬁcant PVL, with
persistent increased ﬂow turbulence and shear stress,
may lead to the breakdown of the large molecular
weight vWF and consequently predispose patients to
late bleeding events, potentially contributing to
increased mortality.Whether high molecular weight vWF could be a
clinically useful surrogate marker of signiﬁcant PVL
(or any other states of high shear stress, such as
prosthesis-patient mismatch) in the future needs to
be investigated in a larger population; however, the
report of Spangenberg et al. (4), paired with our pre-
vious ﬁndings (5), suggests that vWF breakdown after
TAVR could be seen as the “missing link” among PVL,
late bleeding events, and its association with
increased mortality.*Philippe Généreux, MD
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The Missing Link?In reply to the letter of Dr. Généreux and colleagues,
we strongly agree with their continuative analysis
of our data that in conjunction with their work on
major late bleeding complications offer a substanti-
ated hypothesis for the paravalvular leakage (PVL)-
associated mortality after transcatheter aortic valve
